Related Contributions

Immunotherapy for Parkinson's disease: Mechanisms and pathways for human use
UNMC takes next step in developing Parkinson’s disease vaccine
Howard Gendelman, et al.
04 Mar 2010
The therapeutic approach is based on the notion that the inciting event that underlies the pathogenesis of Parkinson’s disease (PD) is the accumulation of aggregated proteins within neuronal ... 
DOPAL triggers alpha-synuclein aggregation
Alpha-synuclein Summit
William J. Burke, SLU
11 Feb 2010
Alpha-synuclein (AS) is a normal constituent of neurons. It  becomes toxic when it aggregates to form oligomers or larger aggregates. The movement disorder in Parkinson disease (PD) is due to ... 
Validating PD targets: FK506 binding proteins
POWs: Papers of the Week
Mark Frasier, MJFF
22 Feb 2010
Digging through the POWs, I found this interesting paper from Veerle Baekelandt's group describing the role of FK506 binding proteins (FKBPs) in alpha-synuclein accumulation and alpha-synuclein ... 
Responses: 1
Alpha-synuclein Summit Take-aways
Alpha-synuclein Summit
Michael Sierks, ASU
04 Mar 2010
1)      Alpha-synuclein is an important and validated therapeutic target for PD.  While this was generally accepted at the meeting, this statement is not so generally ... 
Validating PD targets: FK506 binding proteins
POWs: Papers of the Week
Veerle Baekelandt, KU Leuven
02 Mar 2010
I would like to give a response to Mark Frasier’s questions based on our recent paper in J. Neurosci. ... 
Synuclein Summit Take-aways
Alpha-synuclein Summit
Warren Hirst, Pfizer
26 Feb 2010
1) There is still a need for more research to better understand both the normal and pathological functions of alpha-synuclein.  This will allow for the development of novel therapeutics ... 
Synuclein Summit Take-aways
Alpha-synuclein Summit
Evangelia Emmanouilidou, BioAcademy
26 Feb 2010
1. There is an increasing interest for the development of alpha-synuclein-based imaging techniques, especially for ones targeted to specific species. However, it seems like much more work is needed ... 
Top Points from the Synuclein Summit
Alpha-synuclein Summit
Poul H Jensen, Aarhus
26 Feb 2010
PD is not only a dopamine deficiency disease – we should focus on the other aspects of the disease progression to prevent the wide spread disabling pathogenesis Identification of ... 
For pre-clinical PD models why not look for neuro-protection in pre-clinical pre-motor PD brain regions?
What are the best methods for testing the efficacy of novel neuroprotective therapeutics in pre-clinical models?
Veronica Miller, Wadsworth
24 Feb 2010
There are an abundence of emerging pathological and imaging studies from patients with Lewy Body diseases which strongly suggest that non-dopaminergic neurons are dysfunctional at early ... 
New review on placebo response
What are the biological and psychosocial mechanisms of the placebo response, and how can we manage and/or tap the placebo response in PD clinical trials?
Alison Urkowitz, MJFF, et al.
19 Feb 2010
The recent review by Drs. Finniss, Kaptchuk, Miller and Benedetti of the placebo effect in clinical research explores the mechanistic, clinical and ethical questions that surround this complex ...